Browse > Article
http://dx.doi.org/10.3904/kjim.2012.27.2.143

Steroid Response in Refractory Asthmatics  

Jang, An-Soo (Department of Internal Medicine, Soonchunhyang University Bucheon Hospital)
Publication Information
The Korean journal of internal medicine / v.27, no.2, 2012 , pp. 143-148 More about this Journal
Abstract
Inhaled glucocorticosteroids are currently the most effective anti-inflammatory controller medications for treating persistent asthma. The efficacies of glucocorticoids include reducing asthma symptoms, reducing exacerbation frequency, improving quality of life, improving lung function, decreasing airway hyperresponsiveness, controlling airway inflammation, and reducing mortality. However, the treatment response to glucocorticosteroids in asthmatics varies, and certain subtypes of asthma, such as refractory asthma, respond poorly to high-dose inhaled glucocorticoid and systemic steroids. The medical costs of treating refractory asthmatics represent about 50% of the total healthcare cost for asthma. A thorough understanding of the mechanisms of glucocorticoid action, patient responses to glucocorticoids, and steroid resistance observed in refractory asthmatics is necessary for the targeted development of therapeutic drugs. This review discusses the characteristics of severe refractory asthmatics and the mechansms of steroid response and resistance in asthma treatment.
Keywords
Glucocorticoids; Drug resistance; Asthma;
Citations & Related Records
연도 인용수 순위
  • Reference
1 The Korean Academy of Asthma, Allergy and Clinical Immunology. Treatment 2007 Korea adult asthma treatment guideline [Internet]. Seoul (KR): The Korean Academy of Asthma, Allergy and Clinical Immunology, c2005 [cited 2012 Mar 20]. Available from: http://www.allergy.or.kr.
2 The Korean Academy of Asthma, Allergy and Clinical Immunology. Treatment guideline of asthma in Korea [Internet]. Seoul (KR): The Korean Academy of Asthma, Allergy and Clinical Immunology, c2005 [cited 2012 Mar 20]. Available from: http://www.allergy.or.kr.
3 National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma (EPR-3) [Internet]. Bethesda (MD): National Heart, Lung, and Blood Institute, 2007 [cited 2012 Mar 20]. Available from: http://www.nhlbi. nih.gov/guidelines/asthma.
4 James AL, Maxwell PS, Pearce-Pinto G, Elliot JG, Carroll NG. The relationship of reticular basement membrane thickness to airway wall remodeling in asthma. Am J Respir Crit Care Med 2002;166(12 Pt 1):1590-1595.   DOI
5 Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997;111:852-857.   DOI   ScienceOn
6 Reed CE. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 1999;103:539-547.   DOI   ScienceOn
7 Ten Hacken NH, Postma DS, Timens W. Airway remodeling and long-term decline in lung function in asthma. Curr Opin Pulm Med 2003;9:9-14.   DOI   ScienceOn
8 Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy 2003;33:1622-1628.   DOI   ScienceOn
9 Wenzel S. Severe/fatal asthma. Chest 2003;123(3 Suppl):405S-410S.
10 Wenzel S. Severe asthma: epidemiology, pathophysiology and treatment. Mt Sinai J Med 2003;70:185-190.
11 Heaney LG, Robinson DS. Severe asthma treatment: need for characterizing patients. Lancet 2005;365:974-976.   DOI   ScienceOn
12 Heaney LG, Conway E, Kelly C, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003;58:561-566.   DOI   ScienceOn
13 Stirling RG, Chung KF. Severe asthma: definition and mechanisms. Allergy 2001;56:825-840.   DOI   ScienceOn
14 Afzal M, Tharratt RS. Mechanical ventilation in severe asthma. Clin Rev Allergy Immunol 2001;20:385-397.   DOI   ScienceOn
15 Robinson DS, Campbell DA, Durham SR, et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003;22:478-483.   DOI   ScienceOn
16 Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions: American Thoracic Society. Am J Respir Crit Care Med 2000;162:2341-2351.   DOI   ScienceOn
17 The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470-477.   DOI   ScienceOn
18 Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J 1998;12:1209-1218.   DOI   ScienceOn
19 Chung KF, Godard P, Adelroth E, et al. Difficult/therapyresistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999;13:1198-1208.
20 Chu HW, Trudeau JB, Balzar S, Wenzel SE. Peripheral blood and airway tissue expression of transforming growth factor beta by neutrophils in asthmatic subjects and normal control subjects. J Allergy Clin Immunol 2000;106:1115-1123.   DOI   ScienceOn
21 Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma. Allergy 2005;60:23-29.   DOI   ScienceOn
22 National Asthma Education and Prevention Program. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics-2002. J Allergy Clin Immunol 2002;110(C):S141-S219.   DOI
23 Sandford AJ, Chagani T, Zhu S, et al. Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol 2000;106(1 Pt 1):135-140.   DOI
24 Spiteri MA, Bianco A, Strange RC, Fryer AA. Polymorphisms at the glutathione S-transferase, GSTP1 locus: a novel mechanism for susceptibility and development of atopic airway inflammation. Allergy 2000;55 Suppl 61:15-20.   DOI   ScienceOn
25 Chu HW, Balzar S, Westcott JY, et al. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. Clin Exp Allergy 2002;32:1558-1565.   DOI   ScienceOn
26 Szalai C, Kozma GT, Nagy A, et al. Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol 2001;108:375-381.   DOI   ScienceOn
27 Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989;140:1745-1753.   DOI   ScienceOn
28 Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-1008.   DOI   ScienceOn
29 Jang AS, Lee JH, Park SW, et al. Factors inf luencing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma. Chest 2005;128:1140-1145.   DOI   ScienceOn
30 Vignola AM, Mirabella F, Costanzo G, et al. Airway remodeling in asthma. Chest 2003;123(3 Suppl):417S-422S.
31 Takeyama K, Fahy JV, Nadel JA. Relationship of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med 2001;163:511-516.   DOI   ScienceOn
32 Carroll NG, Mutavdzic S, James AL. Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002;19:879-885.   DOI   ScienceOn
33 Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006;533:2-14.   DOI   ScienceOn
34 Leung DY, Hamid Q, Vottero A, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997;186:1567-1574.   DOI   ScienceOn
35 Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005;172:149-160.   DOI   ScienceOn
36 Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004;1:264-268.
37 Chung KF. Individual cytokines contributing to asthma pathophysiology: valid targets for asthma therapy? Curr Opin Investig Drugs 2003;4:1320-1326.
38 Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004;3:831-844.   DOI   ScienceOn
39 Hedley ML. Gene therapy of chronic inflammatory disease. Adv Drug Deliv Rev 2000;44:195-207.   DOI   ScienceOn
40 Bryan SA, Leckie MJ, Hansel TT, Barnes PJ. Novel therapy for asthma. Expert Opin Investig Drugs 2000;9:25-42.   DOI   ScienceOn
41 Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-1087.   DOI   ScienceOn